18th Nov 2026 05:55
GSK PLC - London-based pharmaceutical company - US Food & Drug Administration grants accelerated approval to Nelkarmi, also known as neladalkib, for adults with previously-treated advanced or metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer. The approval was based on trial results that confirmed an overall response rate of 49% with a duration of response of six or more months in 76% of responders and 12 plus months in 52% of responders. The approval came before the original FDA target action date of November 27 and Nelkarmi previously received FDA's breakthrough therapy and orphan drug designations.
Chief Scientific Officer Tony Wood says: "Nelkarmi is our second new medicine approved in lung cancer this year. It was designed to help address key challenges of ALK-positive non-small cell lung cancer through its broad coverage of ALK resistance mutations, ability to cross the blood-brain barrier and high target selectivity. ALK-positive patients are often younger and can remain on treatment for years, making effective and tolerable new treatment options especially important, and we are pleased to bring this innovation to patients in the US."
Current stock price: 1,912.50 pence
12-month change: up 7.0%
By Elijah Dale, Alliance News senior reporter Asia-Pacific
Comments and questions to [email protected]
Copyright 2026 Alliance News Ltd. All Rights Reserved.
Related Shares:
Glaxosmithkline